Skip to main content

Balyasny Asset Management L.P.

Position in DNLI — Denali Therapeutics Inc.

CIK 1218710 Chicago, IL

Position in DNLI

as of Jun 30, 2026 · filed Aug 14, 2026
Position Value
$0
-$3,746,073 QoQ
Shares Held
0
-100.0% QoQ
Ownership
0.000%
of shares outstanding
% of Portfolio
0.00%
of 13F equity value
Holder Rank
not a current holder
Holding Since
Mar 2020
17 quarters on record

Common Shares in DNLI Over Time

Shares Held

Position Value (USD)

Derivatives in DNLI

reported options exposure · as of Jun 30, 2026
CallValue
$11,131,616
CallShares
432,800
PutValue
$0
PutShares
0

Notional value of option positions as reported on Form 13F. Calls and puts are disclosed separately and do not net against the common-share stake above.

Position in Biotechnology

Healthcare · as of Jun 30, 2026

Balyasny Asset Management L.P. holds $2,350,910,046 across 177 Biotechnology names.

# Ticker Company Shares Value (USD) Open

All Filings in DNLI

Export CSV
17 filing rows on record
Report Date Value (USD) Shares
2026-06-30 $11,131,616 432,800
2026-03-31 $3,746,073 195,108
2025-03-31 $225,609 16,595
2024-12-31 $8,479,588 416,074
2024-09-30 $1,313,996 45,108
2024-06-30 $2,800,610 120,612
2024-03-31 $7,449,314 363,027
2023-12-31 $5,592,197 260,587
2022-12-31 $36,514 1,313
2022-09-30 $767,250 25,000
2021-12-31 $574,180 12,874
2021-09-30 $321,063 6,364
2021-06-30 $7,995,702 101,934
2021-03-31 $3,888,624 68,102
2020-12-31 $4,194,198 50,074
2020-09-30 $2,291,686 63,960
2020-03-31 $950,197 54,266